Loading...

Homepage-2

ABOUT SEEKYO

SEEKYO® is a privately-owned biotech company developing the next generation of chemotherapies, providing cancer patient efficient treatment without adverse effects.

We are designing smart drugs that selectively target the microenvironment of solid tumors while sparing healthy tissues.

Loading

SCIENCE

Chemotherapy is one of the main therapeutic option for cancer patients.
However, most anticancer drugs used clinically lack any intrinsic selectivity, causing severe side effects as the result of their toxicity toward healthy tissues.

Chemotherapy is one of the main therapeutic option for cancer patients.

However, most anticancer drugs used clinically lack any intrinsic selectivity, causing severe adverse effects as the result of their toxicity toward healthy tissues

10

Millions deaths in the world due to cancer

4700

new cancer diagnoses each day around the world

43

% of all cancer diagnosed are solid tumors (lung, breast, prostate...)

36

% of death are due solid tumors cancers (lung, breast, prostate...)

THERAPEUTIC NEEDS

Oncology treatment without adverse effects
Selectivity towards cancer versus healthy tissues
Specific cancer hallmarks

With the aim of offering improved treatments to cancer patients, SEEKYO‘s therapeutic vectors are

01

HARMLESS

Transport of potent anticancer agents in an innocuous manner toward safe tissues
02

EFFICIENT

Efficient recognition of malignant specificities
03

SELECTIVE

Controlled release of the parent drug exclusively at the tumor site

COMPETITIVE ADVANTAGES

Strong in vivo results
Versatile linker technology
Target tumor microenvironnement

THERAPEUTIC VECTORS

Smart drug targeting solid tumors
Cytotoxicity activity triggered exclusively in malignant tissues
No adverse effect

MARKET OFFER

Strong growing market (>$14b)
Custom design solutions for partners
Innovative drug candidates

TECHNOLOGY

SEEKYO®’s unique technology comprises a molecular platform enabling the custom design of almost any type of therapeutic vector.

This versatile linker technology offers the possibility to design “on demand” the most appropriate targeting assembly in order to treat a given malignancy, based on its unique tumor-associated specificities.

SEEKYO®’s self-immolative linker can gather in a single molecular entity:

  • an anticancer agent
  • a targeting unit
  • an enzymatic trigger

The versatility of the technology allows:

DRUG DEVELOPMENT

The development of the next generation of
smart therapeutic vectors targeting the
microenvironment’s hallmarks

INDUSTRIAL COLLABORATION

In optimizing the efficacy of current
Antibody Drug Conjugates (ADC)

.

PIPELINE

MEDIA

Email Address

contact@seekyo-therapeutics.com

Address

4 rue Carol Heitz
86000 POITIERS
FRANCE